Mutual of America Capital Management LLC Has $1.64 Million Stock Holdings in Haemonetics Corporation (NYSE:HAE)

Mutual of America Capital Management LLC decreased its position in shares of Haemonetics Corporation (NYSE:HAE) by 2.5% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,855 shares of the medical instruments supplier’s stock after selling 676 shares during the period. Mutual of America Capital Management LLC owned 0.05% of Haemonetics worth $1,643,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. CWC Advisors LLC. lifted its position in shares of Haemonetics by 7.4% in the fourth quarter. CWC Advisors LLC. now owns 3,083 shares of the medical instruments supplier’s stock worth $241,000 after buying an additional 212 shares during the last quarter. Vise Technologies Inc. grew its stake in shares of Haemonetics by 8.7% in the 4th quarter. Vise Technologies Inc. now owns 2,825 shares of the medical instruments supplier’s stock valued at $221,000 after purchasing an additional 225 shares during the period. HighTower Advisors LLC grew its stake in shares of Haemonetics by 7.8% in the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier’s stock valued at $262,000 after purchasing an additional 244 shares during the period. TD Waterhouse Canada Inc. acquired a new position in shares of Haemonetics in the 4th quarter worth approximately $25,000. Finally, KBC Group NV boosted its holdings in shares of Haemonetics by 19.9% in the 1st quarter. KBC Group NV now owns 2,417 shares of the medical instruments supplier’s stock worth $154,000 after acquiring an additional 401 shares in the last quarter. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Stock Performance

Shares of Haemonetics stock opened at $72.55 on Monday. Haemonetics Corporation has a fifty-two week low of $55.30 and a fifty-two week high of $94.99. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.62 and a quick ratio of 0.99. The firm has a market capitalization of $3.49 billion, a P/E ratio of 21.92, a P/E/G ratio of 1.18 and a beta of 0.39. The company’s 50 day moving average price is $71.63 and its two-hundred day moving average price is $67.79.

Haemonetics (NYSE:HAE) last issued its quarterly earnings results on Thursday, May 8th. The medical instruments supplier reported $1.24 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.02. The company had revenue of $330.60 million for the quarter, compared to analyst estimates of $329.38 million. Haemonetics had a net margin of 12.32% and a return on equity of 26.37%. Haemonetics’s revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.90 earnings per share. On average, equities analysts forecast that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Robert W. Baird began coverage on Haemonetics in a report on Thursday, June 26th. They set an “outperform” rating and a $87.00 price objective on the stock. Raymond James Financial reiterated a “strong-buy” rating and set a $105.00 target price (down previously from $115.00) on shares of Haemonetics in a report on Friday, May 9th. Wall Street Zen downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Tuesday, May 13th. Baird R W upgraded shares of Haemonetics to a “strong-buy” rating in a research note on Wednesday, June 25th. Finally, Citigroup upgraded shares of Haemonetics from a “neutral” rating to a “buy” rating and set a $90.00 price objective for the company in a research report on Wednesday, July 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, Haemonetics has an average rating of “Moderate Buy” and a consensus price target of $97.30.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.